Literature DB >> 19553327

Human immunodeficiency virus type 1 escapes from interleukin-2-producing CD4+ T-cell responses without high-frequency fixation of mutations.

R Brad Jones1, Feng-Yun Yue, Xiao Xiao Jenny Gu, Diana V Hunter, Shariq Mujib, Gabor Gyenes, Rosemarie D Mason, Ruqaya Mohamed, Kelly S MacDonald, Colin Kovacs, Mario A Ostrowski.   

Abstract

The presence of interleukin-2 (IL-2)-producing human immunodeficiency virus type 1 (HIV-1)-specific CD4(+) T-cell responses has been associated with the immunological control of HIV-1 replication; however, the causal relationship between these factors remains unclear. Here we show that IL-2-producing HIV-1-specific CD4(+) T cells can be cloned from acutely HIV-1-infected individuals. Despite the early presence of these cells, each of the individuals in the present study exhibited progressive disease, with one individual showing rapid progression. In this rapid progressor, three IL-2-producing HIV-1 Gag-specific CD4(+) T-cell responses were identified and mapped to the following optimal epitopes: HIVWASRELER, REPRGSDIAGT, and FRDYVDRFYKT. Responses to these epitopes in peripheral blood mononuclear cells were monitored longitudinally to >1 year postinfection, and contemporaneous circulating plasma viruses were sequenced. A variant of the FRDYVDRFYKT epitope sequence, FRDYVDQFYKT, was observed in 1/21 plasma viruses sequenced at 5 months postinfection and 1/10 viruses at 7 months postinfection. This variant failed to stimulate the corresponding CD4(+) T-cell clone and thus constitutes an escape mutant. Responses to each of the three Gag epitopes were rapidly lost, and this loss was accompanied by a loss of antigen-specific cells in the periphery as measured by using an FRDYVDRFYKT-presenting major histocompatibility complex class II tetramer. Highly active antiretroviral therapy was associated with the reemergence of FRDYVDRFYKT-specific cells by tetramer. Thus, our data support that IL-2-producing HIV-1-specific CD4(+) T-cell responses can exert immune pressure during early HIV-1 infection but that the inability of these responses to enforce enduring control of viral replication is related to the deletion and/or dysfunction of HIV-1-specific CD4(+) T cells rather than to the fixation of escape mutations at high frequencies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19553327      PMCID: PMC2738181          DOI: 10.1128/JVI.00433-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes.

Authors:  Edith M Janssen; Edward E Lemmens; Tom Wolfe; Urs Christen; Matthias G von Herrath; Stephen P Schoenberger
Journal:  Nature       Date:  2003-02-09       Impact factor: 49.962

2.  Requirement for CD4 T cell help in generating functional CD8 T cell memory.

Authors:  Devon J Shedlock; Hao Shen
Journal:  Science       Date:  2003-04-11       Impact factor: 47.728

3.  HIV-1-specific CD4+ T-cell responses are not associated with significant viral epitope variation in persons with persistent plasma viremia.

Authors:  John R Koeppe; Thomas B Campbell; Eric L Rapaport; Cara C Wilson
Journal:  J Acquir Immune Defic Syndr       Date:  2006-02-01       Impact factor: 3.731

4.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition.

Authors:  R E Phillips; S Rowland-Jones; D F Nixon; F M Gotch; J P Edwards; A O Ogunlesi; J G Elvin; J A Rothbard; C R Bangham; C R Rizza
Journal:  Nature       Date:  1991-12-12       Impact factor: 49.962

5.  High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation.

Authors:  A C McNeil; W L Shupert; C A Iyasere; C W Hallahan; J A Mican; R T Davey; M Connors
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

6.  Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells.

Authors:  A Bertoletti; A Sette; F V Chisari; A Penna; M Levrero; M De Carli; F Fiaccadori; C Ferrari
Journal:  Nature       Date:  1994-06-02       Impact factor: 49.962

7.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

8.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

9.  Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection.

Authors:  E S Daar; T Moudgil; R D Meyer; D D Ho
Journal:  N Engl J Med       Date:  1991-04-04       Impact factor: 91.245

10.  PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection.

Authors:  Constantinos Petrovas; Joseph P Casazza; Jason M Brenchley; David A Price; Emma Gostick; William C Adams; Melissa L Precopio; Timothy Schacker; Mario Roederer; Daniel C Douek; Richard A Koup
Journal:  J Exp Med       Date:  2006-09-05       Impact factor: 14.307

View more
  15 in total

1.  Lack of association between HLA class II alleles and in vitro replication capacities of recombinant viruses encoding HIV-1 subtype C Gag-protease from chronically infected individuals.

Authors:  Jaclyn K Wright; Zabrina L Brumme; Boris Julg; Mary van der Stok; Zenele Mncube; Xiaojiang Gao; Jonathan M Carlson; Philip J R Goulder; Bruce D Walker; Mark A Brockman; Thumbi Ndung'u
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

2.  Cooperativity of HIV-Specific Cytolytic CD4 T Cells and CD8 T Cells in Control of HIV Viremia.

Authors:  Susan Johnson; Michael Eller; Jeffrey E Teigler; Sebastien M Maloveste; Bruce T Schultz; Damien Z Soghoian; Richard Lu; Alexander F Oster; Agnès-Laurence Chenine; Galit Alter; Ulf Dittmer; Mary Marovich; Merlin L Robb; Nelson L Michael; Diane Bolton; Hendrik Streeck
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

3.  Human endogenous retrovirus K(HML-2) Gag- and Env-specific T-cell responses are infrequently detected in HIV-1-infected subjects using standard peptide matrix-based screening.

Authors:  R Brad Jones; Vivek M John; Diana V Hunter; Eric Martin; Shariq Mujib; Vesna Mihajlovic; Peter C Burgers; Theo M Luider; Gabor Gyenes; Neil C Sheppard; Devi Sengupta; Ravi Tandon; Feng-Yun Yue; Erika Benko; Colin Kovacs; Douglas F Nixon; Mario A Ostrowski
Journal:  Clin Vaccine Immunol       Date:  2011-12-28

4.  HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary isolates.

Authors:  R Brad Jones; Keith E Garrison; Shariq Mujib; Vesna Mihajlovic; Nasra Aidarus; Diana V Hunter; Eric Martin; Vivek M John; Wei Zhan; Nabil F Faruk; Gabor Gyenes; Neil C Sheppard; Ingrid M Priumboom-Brees; David A Goodwin; Lianchun Chen; Melanie Rieger; Sophie Muscat-King; Peter T Loudon; Cole Stanley; Sara J Holditch; Jessica C Wong; Kiera Clayton; Erick Duan; Haihan Song; Yang Xu; Devi SenGupta; Ravi Tandon; Jonah B Sacha; Mark A Brockman; Erika Benko; Colin Kovacs; Douglas F Nixon; Mario A Ostrowski
Journal:  J Clin Invest       Date:  2012-11-12       Impact factor: 14.808

Review 5.  T cell immunity in acute HIV-1 infection.

Authors:  Hendrik Streeck; Douglas F Nixon
Journal:  J Infect Dis       Date:  2010-10-15       Impact factor: 5.226

6.  HIV controller CD4+ T cells respond to minimal amounts of Gag antigen due to high TCR avidity.

Authors:  Benoît Vingert; Santiago Perez-Patrigeon; Patricia Jeannin; Olivier Lambotte; Faroudy Boufassa; Fabrice Lemaître; William W Kwok; Ioannis Theodorou; Jean-François Delfraissy; Jacques Thèze; Lisa A Chakrabarti
Journal:  PLoS Pathog       Date:  2010-02-26       Impact factor: 6.823

7.  HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term.

Authors:  Benoît Vingert; Daniela Benati; Olivier Lambotte; Pierre de Truchis; Laurence Slama; Patricia Jeannin; Moran Galperin; Santiago Perez-Patrigeon; Faroudy Boufassa; William W Kwok; Fabrice Lemaître; Jean-François Delfraissy; Jacques Thèze; Lisa A Chakrabarti
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

8.  DNA Vaccination by Electroporation Amplifies Broadly Cross-Restricted Public TCR Clonotypes Shared with HIV Controllers.

Authors:  Madhura Mukhopadhyay; Moran Galperin; Mandar Patgaonkar; Sandhya Vasan; David D Ho; Alexandre Nouël; Mathieu Claireaux; Daniela Benati; Olivier Lambotte; Yaoxing Huang; Lisa A Chakrabarti
Journal:  J Immunol       Date:  2017-10-09       Impact factor: 5.422

9.  Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells.

Authors:  R Brad Jones; Stephanie Mueller; Sudha Kumari; Vlad Vrbanac; Shy Genel; Andrew M Tager; Todd M Allen; Bruce D Walker; Darrell J Irvine
Journal:  Biomaterials       Date:  2016-11-25       Impact factor: 12.479

10.  CD8+ and CD4+ cytotoxic T cell escape mutations precede breakthrough SIVmac239 viremia in an elite controller.

Authors:  Benjamin J Burwitz; Juan Pablo Giraldo-Vela; Jason Reed; Laura P Newman; Alexander T Bean; Francesca A Nimityongskul; Philip A Castrovinci; Nicholas J Maness; Enrique J Leon; Richard Rudersdorf; Jonah B Sacha
Journal:  Retrovirology       Date:  2012-11-06       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.